4$\pi$ Planning for the Reduction of Predicted Hematologic Toxicity Risk in Cervical Cancer Radiotherapy

Haotian Feng; Ke Sheng; Qifan Xu; Yan Kong

REVIEW 4 major objections 6 minor 3 references

4$\pi$ Planning for the Reduction of Predicted Hematologic Toxicity Risk in Cervical Cancer Radiotherapy

T0 review · 4 major / 6 minor · reviewed 2026-08-16 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Replacing coplanar VMAT with 4π non-coplanar planning is predicted to reduce acute hematologic toxicity risk by about 23% in cervical cancer radiotherapy, based on a radiomics-based model applied to replanned dose distributions.

desk verdict The dosimetric core is real; the headline 23% clinical risk-reduction claim is not supported by the paper's own full-pipeline bootstrap. read the letter →

arxiv 2608.12656 v1 pith:DSJRPRCU submitted 2026-08-12 physics.med-ph

Haotian Feng , Yan Kong , Qifan Xu , Ke Sheng This is my paper · ORCID

classification physics.med-ph

keywords cervicalcancerhematologictoxicity4πnon-coplanarradiotherapyradiomicsmachinelearningbonemarrowsparingVMATriskprediction

verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Standard coplanar radiotherapy for cervical cancer irradiates the pelvic bones, which contain much of the body's blood-forming marrow, leading to acute hematologic toxicity. The paper replaces standard coplanar VMAT plans with 4π non-coplanar plans for 114 retrospective cervical cancer patients and measures the dosimetric improvement. It then trains an elastic-net logistic regression model combining CT radiomic, clinical, and dosimetric features to predict grade≥2 acute hematologic toxicity, reaching an AUC of 0.79. Applying this model to the replanned dose distributions predicts a 23% relative reduction in hematologic toxicity risk with 4π planning compared with VMAT (risk ratio 0.77, 95% CI 0.75–0.79). If this prediction holds, 4π planning would be a practical way to reduce a common, dose-limiting side effect of cervical cancer radiotherapy using only standard CT data.

What carries the argument

Two machines carry the argument. The first is the 4π non-coplanar planning engine, an ultra-high-performance parallel (UHPP) optimizer that starts from 1,162 candidate beams spaced 6° apart, prunes to roughly 400 collision-free directions, and splits the cervical PTV into four equal-volume sub-cuboids with separate isocenters so the 20 cm field limit is respected. The second is the toxicity predictor: an elastic-net logistic regression that takes about 100 selected CT radiomic features plus clinical and dosimetric features and outputs a probability of grade≥2 acute hematologic toxicity, trained and evaluated with 5-fold cross-validation. The dose-volume metrics V10Gy through V40Gy in pelvic bone regions are the bridge: they are strongly reduced by 4π and are the features the risk model leans on.

What would settle it

A prospective randomized trial in which cervical cancer patients are assigned to VMAT or 4π planning and grade≥2 hematologic toxicity is scored from blood counts would settle it: the model predicts a 23% relative reduction, so an observed reduction clearly outside the 95% confidence interval, or none at all, would falsify the central claim.

Watch

Extended reading notes

Core claim

On its own terms, the paper establishes two linked findings. First, 4π non-coplanar optimization reduces pelvic bone marrow dose-volume metrics substantially relative to coplanar VMAT: normalized total pelvic bone V10Gy, V20Gy, V30Gy, and V40Gy fell from 93%/75%/45%/24% to 67%/36%/24%/16%, with comparable PTV coverage and improved or unchanged OAR doses. Second, a predictive model that combines CT radiomic features with clinical and dosimetric features (AUC 0.79) estimates that these dosimetric gains translate into a 23% reduction in predicted acute grade≥2 hematologic toxicity risk, with a risk ratio of 0.77 (95% CI 0.75–0.79) and odds ratio 0.68 (95% CI 0.65–0.71). The authors explicitly note the model had to extrapolate beyond the VMAT dose range and likely underestimated the clinical benefit because of this extrapolation.

Load-bearing premise

The central bet is that the risk model, built from past VMAT plans, correctly predicts toxicity for 4π plans whose bone-marrow doses are much lower than anything the model was trained on.

Editorial extensions

If this is right

Bone-marrow dose reductions of 28–52% across V10Gy–V40Gy are several times larger than the <10–15% reductions reported in coplanar bone-marrow-sparing trials, so 4π appears to open a dose regime that conventional coplanar planning cannot reach.
If the predicted 23% relative risk reduction is real, using 4π for cervical cancer would meaningfully lower rates of grade≥2 leukopenia, neutropenia, and related treatment interruptions.
The prediction model can serve as a triage tool: patients predicted to be high-risk under VMAT are offered 4π, while low-risk patients stay on the faster standard VMAT.
Because the model needs only the routine planning CT and dose-volume data, the risk-assessment workflow requires no functional imaging or extra invasive tests.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

Read strictly, the full-pipeline bootstrap interval (RR 0.80, 95% CI 0.57–1.03) means the 23% point estimate is not statistically robust; my read is that the direction of benefit is credible but the magnitude is not yet pinned down.
Given a monotone dose-response, the 23% figure is likely a floor, not a ceiling, because the model was fit on higher-dose VMAT plans and would under-predict the benefit of the much lower 4π doses.
The same two-step recipe—train a radiomics-based toxicity model on historical plans, then score candidate plan geometries—could be applied to other pelvic toxicities or to plan-class library selection in adaptive radiotherapy.
A prospective randomized comparison is the natural next test: select high-risk patients with the model, treat half with 4π and half with VMAT, and compare observed grade≥2 HT rates; that would also reveal whether the model's extrapolation holds outside the VMAT dose range.

Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Desk Editor's Note

read the letter

The dosimetric core is solid and worth paying attention to; the headline clinical claim is not supported by the paper's own uncertainty analysis. What is new: applying 4π non-coplanar optimization to cervical cancer, with fully integrated beam-angle and fluence optimization, and showing 28–52% reductions in pelvic bone marrow V10–V40 compared with standard VMAT. That is a much larger marrow sparing than the <10–15% typical of coplanar bone-marrow-sparing trials, and the paired statistics in Table F1 are convincing. Using a radiomics/clinical/dosimetric model to score the plans is a reasonable way to turn dosimetry into a patient-level endpoint, and the discussion is transparent about model limitations.

The soft spots are in the clinical claim and in the abstract's phrasing. Section 3.5 reports three risk-ratio estimates. The full-pipeline bootstrap, which is the only one that accounts for model refitting, gives 0.80 with 95% CI 0.57–1.03. That interval crosses 1.0. The abstract instead reports the direct point estimate 0.77 (0.75–0.79) and says the reduction is 23%, omitting the full-pipeline result. The paper says “all estimates consistently indicate a reduced HT risk,” which is misleading: the full-pipeline estimate is consistent with no reduction. Also, the fixed-model bootstrap interval (0.87–0.90) does not contain the point estimate 0.77, so the precision reported in the abstract is not reproducible from the described procedure. On top of that, the model was trained on VMAT dose distributions and applied to 4π doses outside the training range; the authors acknowledge this and speculate that it underestimates benefit, but that could go either way. Finally, the abstract says 4π “significantly reduc[es] dose to other pelvic organs at risk,” but Table F2 shows rectum V40, V45, V50 and D1%/D2% are significantly worse in 4π (e.g., V50Gy 0.08 vs 0.16). Target coverage is maintained by normalization, but “without compromising sparing of other OARs” is false as written.

None of this kills the dosimetric finding. The manuscript deserves a serious referee as a planning and feasibility study, not as evidence of clinical benefit. I would send it out, but request that the abstract and conclusion present the 23% figure as a model-based hypothesis with the full-pipeline uncertainty, and correct the OAR claim. The clinical endpoint needs external or prospective validation before anyone quotes 23%.

Referee Report

4 major / 6 minor

Summary. This manuscript reports a retrospective dosimetric planning study of 114 cervical cancer patients treated with volumetric modulated arc therapy (VMAT). The authors develop a radiomics-based machine learning model to predict acute grade ≥2 hematologic toxicity (HT), then replan each patient with non-coplanar 4π radiotherapy and apply the model to estimate the reduction in predicted HT risk. The dosimetric comparison shows substantial reductions in pelvic bone marrow doses under 4π, and the model achieves an AUC of 0.79. The central clinical claim is a 23% reduction in predicted HT risk (RR 0.77, 95% CI 0.75–0.79). The paper also proposes a risk-based triage strategy for selecting patients for 4π planning.

Significance. If valid, the demonstrated ability to reduce pelvic bone marrow doses by 28–52% without compromising target coverage would be clinically valuable in cervical cancer radiotherapy, and a validated model-based prediction of hematologic toxicity reduction would strengthen the case for 4π planning. The study is also notable for its transparent reporting of multiple bootstrap procedures and for combining radiomics with dosimetric and clinical features in a single predictive pipeline. However, the primary clinical claim is not supported by the paper's own full-pipeline uncertainty analysis, the risk model is applied outside its training range, and the stated OAR-sparing benefit is contradicted by several dosimetric comparisons in the appendix. The dosimetric planning results are likely publishable as a dose-reduction study, but the current framing substantially overstates the evidence for clinical toxicity reduction.

major comments (4)

[Abstract; §3.5] The abstract's central claim of a 23% risk reduction (risk ratio 0.77, 95% CI 0.75–0.79) is not supported by the paper's own full-pipeline bootstrap analysis in Section 3.5, which reports RR 0.80 with 95% CI 0.57–1.03, crossing 1.0. The fixed-model bootstrap (RR 0.88, 95% CI 0.87–0.90) does not contain the abstract's point estimate, so the reported precision is not reproducible from the disclosed procedures. The abstract cites only the direct point estimate, which does not account for model-refitting uncertainty, and the conclusion that 'superior dosimetry should translate to a marked reduction' is therefore not internally consistent with the full uncertainty analysis.
[§4 (Limitations)] The model was trained on historical VMAT plans and then applied to 4π dose distributions that lie substantially outside the training range (e.g., all-region pelvic bone V20Gy falls from 0.75 to 0.36, Table F1). As the authors acknowledge in Section 4, this extrapolation means the model 'likely underestimated the clinical benefits,' which is an admission that the 23% risk reduction is a model extrapolation, not an empirically grounded estimate. Because the reported risk ratio is directly computed from the fitted dose-response model, the magnitude of the predicted benefit cannot be validated by the data in this study, and this limitation is load-bearing for the central claim.
[Abstract; §3.4; Appendix F] The abstract claims 4π planning reduces dose 'without compromising target coverage or sparing of other OARs,' but Appendix F Table F2 shows several OAR dose metrics that significantly increase under 4π: rectum V40Gy (0.45 to 0.48, p=0.02), rectum V45Gy (0.29 to 0.35, p=5e-5), and rectum V50Gy (0.08 to 0.16, p=1e-7). Section 3.4 cherry-picks examples of OAR reductions and ignores these increases, so the stated OAR-sparing claim is directly contradicted by the paper's own dosimetric results.
[§3.5] The method for computing the 'direct point estimate without bootstrapping' and its 95% CI (0.75–0.79) is not described anywhere in the manuscript. Since this is the estimate quoted in the abstract, the lack of a reproducible procedure is a significant presentation gap that affects the main result.

minor comments (6)

[Section 3] Section 3 has no subsection 3.2; the text jumps from 3.1 to 3.3, which is confusing for the reader.
[References] References 16 and 19 are identical (Woods et al. 2022); one should be removed or replaced with a different source.
[Appendix A] The inclusion criterion 'absence of ≥ grade 1 HT or long-term anemia before radiotherapy' is ambiguous; as written it would exclude all patients with any grade of HT, which contradicts the intent of excluding only pre-existing toxicity. Please rephrase.
[Appendix C, Table C1] Table C1 has corrupted column headers (e.g., 'MAX DOSE (GY)', 'MIN DOSE TARGET (GY)') and the layout is not readable; please reformat the table.
[§2.4 / Appendix B] The appendix states that 100 radiomic features were selected, but the main text does not mention this number; the number of selected features should be given in Methods for completeness.
[§3.4] The phrase 'targeting OARs' should be 'target OARs' or simply 'OARs' for grammatical correctness.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the 23% predicted HT risk reduction is a model-based extrapolation, not an input fitted to the 4π endpoint.

full rationale

The paper's derivation chain is: (1) generate 4π plans and compute DVH metrics directly from the optimized dose distributions; (2) train an elastic-net logistic regression model on 114 patients' actual VMAT plans and observed grade 2 or higher hematologic toxicity, selecting features within cross-validation folds and reporting a held-out AUC of 0.79; (3) apply the fixed model to paired VMAT and 4π dose distributions and compute the risk ratio from the predicted probabilities. The risk reduction is therefore a function of independently optimized 4π doses and a model fitted to real toxicity labels, not a parameter fitted to the 4π outcome or defined in terms of the predicted risk. The paper explicitly labels the endpoint as 'predicted' and discloses the key limitations: Section 3.5 reports the full-pipeline bootstrap RR of 0.80 with 95% CI 0.57-1.03, which crosses 1.0, and Section 4 states that because the model was trained on historical VMAT plans and applied to 4π dose distributions, it 'likely underestimated the clinical benefits' due to extrapolation. These are statistical and extrapolation concerns, not circularity. The abstract's choice of the direct point estimate (RR 0.77) over the full-pipeline bootstrap is a reporting inconsistency, but it does not make the derivation self-referential. Self-citations to the UHPP 4π planning framework and to a prior dosiomics study are methodological and non-load-bearing; they do not smuggle in the target conclusion. No equation or fitted value is reused as an independent prediction by construction.

Assumptions & free parameters 3 free parameters · 4 assumptions · 0 invented entities

The central numerical claim is the product of fitted model parameters applied to new plans, not an observed clinical outcome. The model's extrapolation is the load-bearing assumption, and its uncertainty is the reason the full-pipeline bootstrap fails to reach significance. No new physical entities are introduced.

free parameters (3)

Elastic-net logistic regression coefficients = not reported
The predicted risk reduction is computed from this fitted model; coefficients are learned from the 114-patient VMAT cohort and determine the RR and OR.
Number of selected radiomic features = 100
Chosen from an AUC scan over feature-set sizes; this choice affects the fitted model and therefore the predicted risk.
4π optimization weights and constraints = Table C1
OAR weights, max doses, and ring constraints are hand-chosen by the authors and directly shape the dosimetric comparison and the resulting predictions.

assumptions (4)

domain assumption The model trained on VMAT dose distributions is valid for 4π dose distributions outside the training range
Section 3.5 applies the model to 4π plans, and Section 4 explicitly acknowledges the extrapolation and states the model likely underestimates benefit.
domain assumption CT radiomic features capture individual hematopoietic reserve
The paper invokes refs 30-32 for this link, but the connection is indirect and is itself flagged as a limitation in the Discussion.
domain assumption The UHPP 4π dose calculation using collapsed-cone convolution with Monte Carlo validation is accurate
The 4π dose is computed with the authors' UHPP framework (ref 20); no independent verification is provided in this paper.
standard math Standard statistical assumptions for ANOVA F-test feature selection, 5-fold CV, and paired dosimetric tests hold
These are standard tools, but the small sample size relative to 100 selected features raises overfitting concerns that the paper itself acknowledges.

how reviews work

0 comments

Cite this review

Pith. "Pith review of 4$\pi$ Planning for the Reduction of Predicted Hematologic Toxicity Risk in Cervical Cancer Radiotherapy." pith.science (2026). https://pith.science/paper/DSJRPRCU

@misc{pith2026260812656,
  author       = {Pith},
  title        = {Pith review of: 4$\pi$ Planning for the Reduction of Predicted Hematologic Toxicity Risk in Cervical Cancer Radiotherapy},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/DSJRPRCU}},
  note         = {Machine review of arXiv:2608.12656}
}

abstract

Purpose: In conventional coplanar radiotherapy for cervical cancer, nearby pelvic bones receive high radiation doses, increasing the risk of acute hematologic toxicity (HT). This study aims to estimate the HT risk reduction achievable with non-coplanar (4$\pi$) radiotherapy. Methods: We retrospectively analyzed 114 cervical cancer patients treated with coplanar volumetric modulated arc therapy (VMAT) between 2021 and 2023. Radiomic features from planning CTs were extracted and combined with clinical and dosimetric data to train predictive machine learning models. Patients were then replanned using integrated non-coplanar beam orientation and fluence map optimization (4$\pi$ planning). The top performing model was applied to these new plans to evaluate potential HT reduction. Results: Models combined radiomics, clinical, and dosimetric features achieved the highest predictive performance (AUC = 0.79). Feature importance analysis highlighted CT radiomic and dosimetric variables as the strongest predictors. Compared to VMAT, 4$\pi$ non-coplanar planning significantly reduced doses to the bone marrow (V10Gy, V20Gy, V30Gy, and V40Gy by 28%, 52%, 47%, and 33%, respectively) while significantly reducing dose to other pelvic organs at risk (OAR). When evaluated by the model, this improved dosimetry translated into a 23% reduction in predicted HT risk (risk ratio: 0.77; 95% CI: 0.75-0.79 and odds ratio: 0.68; 95% CI:0.65-0.71). Conclusions: Non-coplanar 4$\pi$ radiotherapy significantly lowers radiation doses to major pelvic bones during cervical cancer treatment without compromising target coverage or sparing of other OARs. Based on our predictive model, this superior dosimetry should translate to a marked reduction in acute hematologic toxicity.

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

3 extracted references · 3 canonical work pages

[1]

External beam radiation therapy (EBRT), often delivered in combination with brachytherapy and chemotherapy, is a cornerstone in the management of locally advanced disease(2)

Introduction Cervical cancer remains one of the most prevalent malignancies affecting women worldwide, particularly in low and middle-income countries(1). External beam radiation therapy (EBRT), often delivered in combination with brachytherapy and chemotherapy, is a cornerstone in the management of locally advanced disease(2). However, EBRT inevitably ex...

work page 2021
[19]

A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes

Woods KE, Ma TM, Cook KA, et al. A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers. 2022;14:939. 20. Xu Q, Lyu Q, Jiang L, et al. An ultra-high performance parallel (UHPP) framework for complex 4π radiotherapy planning. Phys. Med. Bi...

work page 2022
[31]

Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter? Front Oncol

Yue H, Li X, You J, et al. Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter? Front Oncol. 2024;14:1365897. 32. Shen W, Velasquez G, Chen J, et al. Comparison of the Relationship between Bone Marrow Adipose Tissue and Volumetric Bone Mineral Density in Children...

work page 2024

Pith tools

Reviewed August 16, 2026 · model on record in the stance chip above.

[1] [1]

External beam radiation therapy (EBRT), often delivered in combination with brachytherapy and chemotherapy, is a cornerstone in the management of locally advanced disease(2)

Introduction Cervical cancer remains one of the most prevalent malignancies affecting women worldwide, particularly in low and middle-income countries(1). External beam radiation therapy (EBRT), often delivered in combination with brachytherapy and chemotherapy, is a cornerstone in the management of locally advanced disease(2). However, EBRT inevitably ex...

work page 2021

[2] [19]

A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes

Woods KE, Ma TM, Cook KA, et al. A Prospective Phase II Study of Automated Non-Coplanar VMAT for Recurrent Head and Neck Cancer: Initial Report of Feasibility, Safety, and Patient-Reported Outcomes. Cancers. 2022;14:939. 20. Xu Q, Lyu Q, Jiang L, et al. An ultra-high performance parallel (UHPP) framework for complex 4π radiotherapy planning. Phys. Med. Bi...

work page 2022

[3] [31]

Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter? Front Oncol

Yue H, Li X, You J, et al. Acute hematologic toxicity prediction using dosimetric and radiomics features in patients with cervical cancer: does the treatment regimen matter? Front Oncol. 2024;14:1365897. 32. Shen W, Velasquez G, Chen J, et al. Comparison of the Relationship between Bone Marrow Adipose Tissue and Volumetric Bone Mineral Density in Children...

work page 2024